ArticleBMC health services research2025
Economic evaluation of a robotic chemotherapy compounding system and its service expansion to network hospital in Thailand.
Article in BMC health services research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRobotic systems for chemotherapy preparation offer improved accuracy and staff safety but require substantial capital investment. This study assessed the economic performance of a domestically developed robotic chemotherapy compounding system at Udon Thani Cancer Hospital and its service expansion to a network hospital in Thailand.
methodsA descriptive study with economic evaluation was conducted, including cost-benefit analysis, unit cost analysis, and break-even analysis from both provider and health system perspectives. Data from fiscal year 2023 were used. Direct and indirect costs were assessed, and clinical outcomes were documented. A scenario-based sensitivity analysis was performed to examine cost variations under different capacity utilisation levels.
resultsRobotic preparation had a higher per-dose cost (THB 538 for 4,173 doses) than manual preparation (THB 250 for 20,310 doses), but was associated with total estimated economic benefits of THB 1.88 million, including labour and training savings and improved pharmaceutical care. The break-even point was estimated at 41,802 doses for robotic compounding and 5,122 doses for service expansion. The incremental benefit-cost ratio (IBCR) was 1.566 and increased to 3.018 when including delivery to the network hospital.
conclusionsThe robotic system demonstrated potential economic and operational advantages, particularly when scaled to serve additional facilities. These findings offer preliminary evidence to inform future policy considerations under Thailand's Cancer Service Plan. Further evaluation is needed to assess long-term sustainability and broader system-level outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.